Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region☆
暂无分享,去创建一个
J. Cuzick | C. Wheeler | F. X. Bosch | N. Muñoz | A. Giuliano | S. Kjaer | S. Garland | X. Castellsagué | D. Ferris | E. Myers | K. Ault | A. Saah | J. Paavonen | M. Hernández-Ávila | E. Joura | O. Iversen | W. Huh | A. Luxembourg | M. Steben | H. Sings | G. Pérez | C. Velicer | J. Monsonégo | J. Luna | Darron R. Brown | P. Pitisuttihum | Darron R. Brown | F. Bosch | Joaquín Luna | C. Wheeler
[1] J. Dillner,et al. Long‐term HPV type‐specific risks of high‐grade cervical intraepithelial lesions: A 14‐year follow‐up of a randomized primary HPV screening trial , 2015, International journal of cancer.
[2] J. Cuzick,et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.
[3] J. Dillner,et al. Are 20 human papillomavirus types causing cervical cancer? , 2014, The Journal of pathology.
[4] T. Weiss,et al. Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). , 2014, Cancer epidemiology.
[5] E. Unger,et al. HPV Type Attribution in High-Grade Cervical Lesions: Assessing the Potential Benefits of Vaccines in a Population-Based Evaluation in the United States , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[6] C. Wheeler,et al. Human Papillomavirus Genotype-Specific Prevalence across the Continuum of Cervical Neoplasia and Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[7] Jack Cuzick,et al. Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[8] E. Unger,et al. Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009 , 2014, Cancer Causes & Control.
[9] Maria Hortlund,et al. Targeting Human Papillomavirus to Reduce the Burden of Cervical, Vulvar and Vaginal Cancer and Pre-Invasive Neoplasia: Establishing the Baseline for Surveillance , 2014, PloS one.
[10] P. Castle,et al. Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. , 2013, The Journal of infectious diseases.
[11] T. Weiss,et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease , 2012, Infectious Agents and Cancer.
[12] E. Unger,et al. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions , 2012, Cancer Causes & Control.
[13] D. Gertig,et al. Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact , 2011, Expert review of anti-infective therapy.
[14] N. Muñoz,et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age , 2011, British Journal of Cancer.
[15] C. Wheeler,et al. Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[16] N. Muñoz,et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.
[17] A. Zuckerman,et al. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1995, IARC monographs on the evaluation of carcinogenic risks to humans.
[18] S. Wacholder,et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants , 2009, International journal of cancer.
[19] N. Muñoz,et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial , 2009, The Lancet.
[20] M. Madeleine,et al. A Systematic Review of the Prevalence and Attribution of Human Papillomavirus Types among Cervical, Vaginal, and Vulvar Precancers and Cancers in the United States , 2008, Cancer Epidemiology Biomarkers & Prevention.
[21] S. Goldie,et al. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications , 2008, Reproductive health matters.
[22] F. X. Bosch,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .
[23] Daron G Ferris,et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.
[24] Diane Solomon,et al. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. , 2007, American journal of clinical pathology.
[25] Edson Duarte Moreira Júnior,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.
[26] C. Wheeler,et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.
[27] Cosette M Wheeler,et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.
[28] M. Schiffman,et al. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. , 2001, JAMA.
[29] B. Hankey,et al. Surveillance, Epidemiology, and End Results Program , 1999 .